Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04757610 · ClinicalTrials.gov registry record · Phase 3
OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)
A Phase 3 study, sponsored by Opthea Limited.
- Terminated
- Registry status
- Phase 3
- Development phase
- 986
- Enrollment target
NCT04757610: Clinical Trial Phase 3 study, sponsored by Opthea Limited.
NCT04757610 is a Phase 3 study that was terminated before completion, run by Opthea Limited. The registered enrollment target is 986 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (28% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04757610, a Phase 3 study, was terminated before completion, sponsored by Opthea Limited.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 986 participants
- Enrollment target
Study Summary
A 2-year, phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study. Primary efficacy will be determined at Week 52.
Primary Outcome
To determine the efficacy of intravitreal 2.0 mg OPT-302 when administered in combination with intravitreal 0.5 mg ranibizumab, in participants with neovascular age-related macular degeneration (nAMD), in terms of change in ETDRS BCVA letter score in the study eye from Baseline to Week 52. The primary analysis presented used mixed model for repeated measures in the overall population. (A positive outcome measure means an improvement in ETDRS BCVA letter score from baseline; a negative outcome me
Interventions
- PROCEDURE Sham
- BIOLOGICAL 2.0 mg OPT-302
- BIOLOGICAL 0.5 mg ranibizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 986 participants |
| Start Date | 2021-03-12 |
| Est. Completion | 2025-03-31 |
| Phase | Phase 3 |
Why NCT04757610 stopped before completion
NCT04757610 is an interventional study that assigns participants to a tested intervention. The registered 986 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (28% higher).
The record links to 0 conditions, and to 3 interventions - of which Sham is the first listed.
NCT04757610 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04757610 about?
NCT04757610 is a clinical study titled "OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)". A 2-year, phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study. Primary efficacy will be determined at Week 52.
What is the current status of trial NCT04757610?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 986 participants. The study started on 2021-03-12. Estimated completion is 2025-03-31.
What interventions are being tested in trial NCT04757610?
The interventions under investigation include: Sham (PROCEDURE), 2.0 mg OPT-302 (BIOLOGICAL), 0.5 mg ranibizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04757610?
This trial is sponsored by Opthea Limited, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04757610's enrollment target sits among peer trials
986 320th of 2000 higher than 1,681 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05079841 · 988 participants · Phase 4
The Stimulation To Induce Mothers Study
- NCT05441709 · 990 participants · NA
Furthering Equity Through Infant Feeding EDucation and Support
- NCT06340646 · 990 participants · NA
Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)
- NCT06878261 · 990 participants · Phase 3
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI